Market closedADR
Novartis/$NVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Ticker
$NVS
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Basel, Switzerland
Employees
75,883
Website
Novartis Metrics
BasicAdvanced
$212B
19.18
$5.87
0.53
$2.43
2.16%
Price and volume
Market cap
$212B
Beta
0.53
52-week high
$120.06
52-week low
$92.35
Average daily volume
2.4M
Dividend rate
$2.43
Financial strength
Current ratio
1.035
Quick ratio
0.73
Long term debt to equity
51.974
Total debt to equity
71.162
Dividend payout ratio (TTM)
63.85%
Interest coverage (TTM)
16.22%
Management effectiveness
Return on assets (TTM)
10.09%
Return on equity (TTM)
26.28%
Valuation
Price to earnings (TTM)
19.177
Price to revenue (TTM)
4.392
Price to book
4.42
Price to tangible book (TTM)
-25.55
Price to free cash flow (TTM)
16.361
Dividend yield (TTM)
2.16%
Forward dividend yield
2.16%
Growth
Revenue change (TTM)
10.85%
Earnings per share change (TTM)
-17.36%
3-year revenue growth (CAGR)
5.56%
3-year earnings per share growth (CAGR)
-17.96%
3-year dividend per share growth (CAGR)
4.34%
What the Analysts think about Novartis
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Novartis Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Novartis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Novartis News
AllArticlesVideos
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
GlobeNewsWire·17 hours ago
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
GlobeNewsWire·3 days ago
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
GlobeNewsWire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $212B as of March 31, 2025.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 19.18 as of March 31, 2025.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of March 31, 2025, the dividend rate is $2.4307 and the yield is 2.16%. Novartis has a payout ratio of 63.85% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment date is unconfirmed.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.